

October 28, 2009



SCYNEXIS to Present HCV Data on Novel Cyclophilin Inhibitor SCY-635 at AASLD Annual Meeting

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- Drug discovery company SCYNEXIS, Inc. today announced that supportive data from a preclinical study of the Company's lead product candidate for hepatitis C (HCV), SCY-635, will be presented in a poster session at the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) being held in Boston, MA, October 30-November 3, 2009. SCYNEXIS plans to initiate a Phase 2a combination trial of SCY-635 in patients with HCV in the second quarter of 2010. SCY-635 is a non-immunosuppressive cyclosporin analog that has demonstrated potent suppression of plasma viremia when given as monotherapy to adults with chronic hepatitis C virus infection.

Presentation at AASLD:

Tuesday, November 3, 8:00 AM - 1:00 PM ET: HCV Therapy: Preclinical and Clinical Development Session

Abstract 1595 entitled "Antiviral Activity of the Non-Immunosuppressive Cyclophilin Inhibitor SCY-635 in Combination with Investigational and Approved Anti-HCV Agents" will be presented by SCYNEXIS. In preparation for the Phase 2a clinical trial, the in vitro antiviral activity of SCY-635 was evaluated in multiple two-drug combinations in this preclinical study. The activity of SCY-635 was investigated in combination with non-nucleoside polymerase inhibitors, nucleoside polymerase inhibitors, protease inhibitors (boceprevir, telaprevir), ribavirin and interferon alpha 2b.

About SCYNEXIS

SCYNEXIS is a premier drug discovery and development company delivering effective and innovative drug pipeline solutions to pharmaceutical and global health partners. The Company, which is located in Research Triangle Park, North Carolina, is also developing a proprietary internal pipeline based on cyclophilin inhibitors, a class of drugs that hold significant potential for the treatment of a broad range of diseases. Please visit our website at www.scynexis.com.

Source: SCYNEXIS, Inc.